Navigation Links
Shedding light on cancer cells
Date:9/24/2009

Scientists label cells with coloured or glowing chemicals to observe how basic cellular activities differ between healthy and cancerous cells. Existing techniques for labelling cells are either too slow or too toxic to perform on live cells. Now, a study reviewed by Philip Dawson, a member of Faculty of 1000 Biology and leading authority in chemistry and cell biology, describes a novel labelling technique that uses a chemical reaction to make live cancer cells light up quickly and safely.

Researchers at Massachusetts General Hospital developed a two-step process to specifically tag cancer cells. First, chemically modified antibodies home in on cancer cells. Then a chemical reaction called cycloaddition transfers a dye onto the antibody making the cancer cells glow when viewed through a microscope.

The novel cycloaddition reaction is fast, very specific, and requires minimal manipulation of the cells. Dawson comments that, in combining antibody binding with the cycloaddition, "low signal-to-noise ratios are achieved". This new labelling technique could be used to track the location and activity of anti-cancer drugs, the location of cancer-specific proteins within the cell, or to visualize cancer cells inside a living organism.

Dawson concludes that cycloaddition will allow scientists to observe live cancer cells in the body, leading to a better understanding of cancer's basic processes.


'/>"/>

Contact: Steve Pogonowski
press@f1000.com
Faculty of 1000: Biology and Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Clemson scientists shed light on molecules in living cells
2. September Geology and GSA Today media highlights
3. Highlights from the September 2007 Journal of the American Dietetic Association
4. Genome study shines light on genetic link to height
5. Pig study sheds new light on the colonisation of Europe by early farmers
6. Researchers developing device to predict proper light exposure for human health
7. AGU journal highlights -- Sept. 6, 2007
8. IDEMA Reveals Program Highlights for DISKCON USA 2007
9. Men shed light on the mystery of human longevity, study finds
10. Zebrafish to shed light on human mitochondrial diseases
11. UT researcher sheds new light on hybrid animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: